lthough currently the main focus is diagnostics and biomarker discovery, clinical proteomics includes the identification of new therapeutic targets, drugs and vaccines for better therapeutic outcomes and successful disease prevention. The sequence information of discriminatory polypeptides (biomarkers) defined by CE-MS analysis can be achieved by directly or indirectly interfacing CE with MS/MS instruments.
Figure 2: Urinary proteome map focused on the differential diagnosis of renal diseases. For each CE-MS-defined polypeptide of a given pattern with mass plotted against CE migration time (1), the biomarker-defining parameters (mass, CE migration time, protein ID (2), determined polypeptide sequence (4), and fragment information) can be displayed. In addition, the amplitude distribution of the biomarker presuming a Gaussian distribution (3) and statistical data (5) available for selected specific diseases are shown. MS/MS spectrum of the biomarker (6) completes the biomarker information. NC = Normal Control, DN = Diabetic Nephropathy, FSGS = Focal-segmental Glomerulosclerosis, IgAN = IgA Nephropathy, MCD = Minimal-change Disease, SLE = Lupus Nephritis, MGN = Membranous Glomerulonephritis